HC Wainwright Issues Optimistic Forecast for RCUS Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS forecast for Arcus Biosciences to a loss of $1.00 per share from $1.07, while maintaining a Buy rating and $45 price target.
• Arcus reported a Q2 loss of $0.72 per share, beating expectations of a $0.89 loss, with revenue of $41 million versus the $21.98 million consensus estimate. Revenue nevertheless fell 74.4% year over year.
• Analyst sentiment is broadly favorable, with eight Buy, three Hold and one Sell rating, resulting in a Moderate Buy consensus and average price target of $37.70; institutional investors own 92.89% of the stock.

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for Arcus Biosciences in a research report issued on Thursday, August 6th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($1.00) per share for the quarter, up from their previous forecast of ($1.07). HC Wainwright currently has a "Buy" rating and a $45.00 target price on the stock. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.60) per share. HC Wainwright also issued estimates for Arcus Biosciences' Q4 2026 earnings at ($0.96) EPS, FY2026 earnings at ($4.35) EPS, FY2027 earnings at ($3.23) EPS, FY2028 earnings at ($2.18) EPS, FY2029 earnings at ($1.45) EPS and FY2030 earnings at ($0.61) EPS.

Several other equities research analysts also recently commented on the stock. Wall Street Zen downgraded shares of Arcus Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Morgan Stanley lifted their price objective on shares of Arcus Biosciences from $20.00 to $22.00 and gave the stock an "equal weight" rating in a research report on Monday, May 11th. Leerink Partners set a $47.00 target price on Arcus Biosciences in a research report on Monday, April 20th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Arcus Biosciences in a report on Friday, July 17th. Finally, Truist Financial started coverage on Arcus Biosciences in a report on Monday, May 18th. They set a "buy" rating and a $35.00 price target on the stock. Eight research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $37.70.

Arcus Biosciences Price Performance

RCUS stock opened at $28.67 on Monday. The company has a current ratio of 3.82, a quick ratio of 3.82 and a debt-to-equity ratio of 0.22. Arcus Biosciences has a one year low of $8.88 and a one year high of $31.74. The firm has a market capitalization of $3.65 billion, a PE ratio of -7.35 and a beta of 0.80. The firm has a 50-day moving average of $27.40 and a two-hundred day moving average of $24.27.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.17. The business had revenue of $41.00 million during the quarter, compared to analyst estimates of $21.98 million. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%.The company's revenue for the quarter was down 74.4% compared to the same quarter last year.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, CAO Alexander Azoy sold 2,562 shares of the business's stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $25.77, for a total value of $66,022.74. Following the completion of the sale, the chief accounting officer directly owned 39,581 shares of the company's stock, valued at $1,020,002.37. The trade was a 6.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Juan C. Jaen sold 20,067 shares of the company's stock in a transaction on Friday, July 10th. The stock was sold at an average price of $28.62, for a total transaction of $574,317.54. Following the completion of the sale, the president owned 822,240 shares of the company's stock, valued at $23,532,508.80. This represents a 2.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 102,562 shares of company stock valued at $2,975,354. 7.60% of the stock is currently owned by company insiders.

Institutional Trading of Arcus Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in shares of Arcus Biosciences during the 2nd quarter valued at about $506,113,000. Vanguard Group Inc. boosted its position in Arcus Biosciences by 20.1% during the fourth quarter. Vanguard Group Inc. now owns 7,962,874 shares of the company's stock worth $189,755,000 after purchasing an additional 1,333,421 shares during the period. Suvretta Capital Management LLC grew its holdings in Arcus Biosciences by 40.7% during the fourth quarter. Suvretta Capital Management LLC now owns 5,188,858 shares of the company's stock valued at $123,650,000 after purchasing an additional 1,500,000 shares during the last quarter. Wellington Management Group LLP grew its holdings in Arcus Biosciences by 309.4% during the fourth quarter. Wellington Management Group LLP now owns 5,184,509 shares of the company's stock valued at $123,547,000 after purchasing an additional 3,918,220 shares during the last quarter. Finally, State Street Corp raised its position in shares of Arcus Biosciences by 34.8% in the fourth quarter. State Street Corp now owns 4,576,969 shares of the company's stock valued at $109,069,000 after purchasing an additional 1,182,115 shares during the period. Institutional investors and hedge funds own 92.89% of the company's stock.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company's research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company's lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source